戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 at are perturbed by single-gene mutations in primary immune deficiency.
2 from an autopsy case where the patient had a primary immune deficiency.
3  for lung pathogens present in patients with primary immune deficiency.
4 (NKDs) are an emerging phenotypic subtype of primary immune deficiency.
5 understanding of the molecular basis of many primary immune deficiencies.
6 fer several advantages for the correction of primary immune deficiencies.
7 he enrolled persons was 9 years, and 99% had primary immune deficiencies.
8    Immunology workup results demonstrated no primary immune deficiencies.
9  leukocyte adhesion deficiency are the major primary immune deficiencies affecting phagocytic blood c
10 mportant to conceptualize the association of primary immune deficiencies and autoimmunity.
11 ectly by the genetic defect, including other primary immune deficiencies and inborn errors of metabol
12 se for cell-based therapies for cancer, HIV, primary immune deficiencies, and autoimmune diseases, bu
13      Patients with acquired aplastic anemia, primary immune deficiencies, and congenital bone marrow
14 such as benign overgrowth syndromes, cancer, primary immune deficiency, and metabolic syndrome.
15 nical reality for several of the most severe primary immune deficiencies, as well as other inherited
16     Chronic granulomatous disease (CGD) is a primary immune deficiency characterized by a defect in r
17 ommon variable immune deficiency (CVID) is a primary immune deficiency characterized by low levels of
18  of the inaugural Artificial Intelligence in Primary Immune Deficiencies conference, during which exp
19  dermatitis, food allergy, drug allergy, and primary immune deficiency disease in racial and ethnic u
20 ective levels of antibodies to patients with primary immune deficiency diseases (PIDD) and for prophy
21                              The most severe primary immune deficiency diseases (PIDs) have been succ
22 h American centers studying therapy for rare primary immune deficiency diseases (PIDs), including sev
23                                              Primary immune deficiency diseases arise due to heritabl
24     Chronic granulomatous disease (CGD) is a primary immune deficiency disorder of phagocytes, caused
25 iskott-Aldrich syndrome (WAS) is an X-linked primary immune deficiency disorder resulting from Wiskot
26                                 Persons with primary immune deficiency disorders (PIDD) who receive o
27                               Traditionally, primary immune deficiencies have been defined based on i
28 (PEPD), a cellular dipeptidase implicated in primary immune deficiencies in humans.
29 ciency (CVID), the most frequent symptomatic primary immune deficiency in humans, is a heterogeneous
30 ophil homeostasis using a zebrafish model of primary immune deficiency induced by the human inhibitor
31                 One-by-one, gene therapy for primary immune deficiencies is being brought to the clin
32             These phenotypes usually include primary immune deficiencies, livedo reticularis, and hem
33 we summarize the recent advances in treating primary immune deficiency (PID) disorders by stem cell t
34       With the burgeoning field of genetics, primary immune deficiencies (PIDs) can be diagnosed and
35              Recent studies in patients with primary immune deficiencies (PIDs) have led to important
36 al missense variants in a gene implicated in primary immune deficiency, PLCG2, and a negative regulat
37 s of donors that is used to prevent or treat primary immune deficiency, several infectious diseases,
38 tion in a range of new, genetically defined, primary immune deficiency states; and (iii) experimental
39 ts cause loss of gene function, resulting in primary immune deficiencies such as severe combined immu
40 icacy of the ongoing gene therapy trials for primary immune deficiencies, the first reports of new tr
41                                          The Primary Immune Deficiency Treatment Consortium (PIDTC) e
42                                          The Primary Immune Deficiency Treatment Consortium (PIDTC) e
43                                          The Primary Immune Deficiency Treatment Consortium (PIDTC) i
44                                          The Primary Immune Deficiency Treatment Consortium (PIDTC) i
45                                          The Primary Immune Deficiency Treatment Consortium (PIDTC) i
46                 Application of these revised Primary Immune Deficiency Treatment Consortium 2022 Defi
47                                          The Primary Immune Deficiency Treatment Consortium attempted
48 29 patients with WAS who underwent HCT at 29 Primary Immune Deficiency Treatment Consortium centers f
49 h p47phox CGD who received allogeneic HCT at Primary Immune Deficiency Treatment Consortium centers s
50                                 In 2014, the Primary Immune Deficiency Treatment Consortium published
51 tween 1982 and 2017 who were enrolled in the Primary Immune Deficiency Treatment Consortium SCID stud
52                                          The Primary Immune Deficiency Treatment Consortium was forme
53 bined immunodeficiency (SCID) as part of the Primary Immune Deficiency Treatment Consortium's (PIDTC'
54 n American Society for Immunodeficiency, and Primary Immune Deficiency Treatment Consortium.
55 f 36 patients with CGD recruited through the Primary Immune Deficiency Treatment Consortium.
56 ur review of the literature regarding PML in primary immune deficiencies we found 26 cases, only 54%
57 ition, a diagnosis of secondary ITP due to a primary immune deficiency with immune dysregulation may